Oryzon Genomics, S.A. announced the nomination of ORY-4001, a selective histone deacetylase 6 (HDAC-6) inhibitor, as clinical development candidate for the treatment of certain neurological diseases as Charcot-Marie-Tooth (CMT), Amyotrophic Lateral Sclerosis (ALS) and others. HDAC6 inhibitors have been previously proposed as potentially effective treatments for CMT, ALS and other neurological disorders that lack effective treatments.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.952 EUR | -0.91% | -0.41% | +3.39% |
05-06 | Oryzon Genomics S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-22 | Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.39% | 122M | |
+21.74% | 46.81B | |
-0.97% | 41.37B | |
+47.07% | 41.29B | |
-3.52% | 28.87B | |
+11.12% | 26.06B | |
-19.37% | 19.13B | |
+31.18% | 12.39B | |
-0.04% | 12.08B | |
+0.39% | 11.96B |
- Stock Market
- Equities
- ORY Stock
- News Oryzon Genomics S.A.
- Oryzon Genomics, S.A. Announces Clinical Candidate Nomination of ORY-4001 for the Treatment of CNS Disorders